Briakinumab

From Wikipedia, the free encyclopedia
Briakinumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target IL-12 and IL-23
Clinical data
Legal status investigational
Pharmacokinetic data
Bioavailability N/A
Identifiers
CAS number 339308-60-0
ATC code L04AC09
UNII 978I8M0P8X YesY
Chemical data
Formula C6376H9874N1722O1992S44 
Mol. mass 146.5 kDa
 YesY (what is this?)  (verify)

Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.[1]

Like ustekinumab, the antibody targets the interleukins 12 and 23.[2]

Discovery

The candidate drug was discovered by Cambridge Antibody Technology in collaboration with Abbott.[3][4]

Trials

As of November 2009, Phase III clinical trials for plaque psoriasis[5][6] and a Phase II trial for multiple sclerosis[7] have been completed, and a Phase II trial for Crohn's disease is underway.[8]

Briakinumab was compared to etanercept and placebo in several double-blind trials. The Psoriasis Area Severity Index (PASI) was reduced significantly better than under the comparator treatments. 81–82% of patients under briakinumab, 40–56% under etanercept, and 7% under placebo reached PASI reduction of at least 75%.[9] No head-to-head studies against ustekinumab, the other IL-12/23 inhibitor, are available.

Royalties

This is the second candidate from a deal with Cambridge Antibody Technology that Abbott have taken to late-stage clinical trials. As a result of the protracted royalty dispute over Humira Abbott agreed to pay CAT a reduced royalty of 4.75% on any future sales of ABT-874, from which CAT will pay a portion to the MRC and other licensors (according to CAT's 1997 agreement with the MRC).[10]

References



This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.